Orly Vardeny et al. JCHF 2016;4:

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.

Stephen W. Waldo et al. JACC 2008;51:

Adjusted relative mortality risk

Noriko Kikuchi et al. JACEP 2016;2:

Baseline characteristics of patients

Nat. Rev. Cardiol. doi: /nrcardio

Orly Vardeny et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:

Dileep Raman et al. JACEP 2017;3:

Jose C. Pachon M. et al. JACEP 2015;1:

Belinda Gray et al. JCHF 2013;1:

Simon W. Rabkin et al. JACEP 2017;j.jacep

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Wesley T. O’Neal et al. JACEP 2016;2:

Wayne L. Miller et al. JCHF 2013;1:

John A. Bittl et al. JACC 2016;68:

Mintu P. Turakhia et al. JACEP 2016;2:

Jordan B. King et al. JCHF 2016;4:

G. Michael Felker et al. JCHF 2014;2:

Svend A. Mortensen et al. JCHF 2014;2:

Prabhat Kumar et al. JACEP 2016;j.jacep

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Patient characteristics: American vs Canadian transplant patients

Kenshi Hayashi et al. JACEP 2016;2:

Connie W. Tsao et al. JCHF 2016;4:

Rami Doukky et al. JCHF 2016;4:24-35

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Neal A. Chatterjee et al. JCHF 2014;2:

P. Michael Grossman et al. JCIN 2009;2:

Gordon R. Reeves et al. JCHF 2017;j.jchf

William T. Abraham et al. JCHF 2015;3:

Peter E. Carson et al. JCHF 2015;3:

Maria R. Costanzo et al. JCHF 2016;4:

Jerry D. Estep et al. JCHF 2013;1:

Mintu P. Turakhia et al. JACEP 2016;2:

Simon W. Rabkin et al. JACEP 2017;3:

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Rami Doukky et al. JCHF 2016;4:24-35

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Maneesh Sud et al. JCHF 2017;5:

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

John Rickard et al. JCHF 2013;1:

Maria Rosa Costanzo et al. JCHF 2016;4:95-105

Jordan B. King et al. JCHF 2016;4:

Svend A. Mortensen et al. JCHF 2014;2:

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Davide Capodanno et al. JCIN 2009;2:

Herbert D. Aronow et al. JCIN 2015;8:49-56

Connie W. Tsao et al. JCHF 2016;4:

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Saadia Sherazi et al. JACEP 2015;1:74-80

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Christian Madelaire et al. JCHF 2018;6:

Khadijah Breathett et al. JCHF 2017;5:

Constantijn Franssen et al. JCHF 2016;4:

Dennis M. McNamara et al. JCHF 2014;2:

Pamela E. Scott et al. JACC 2018;71:

Jeffrey Senfield et al. JACEP 2017;3:

Increase of physical activity over time associated with lower HF risk

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Maria R. Costanzo et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Constantijn Franssen et al. JCHF 2016;4:

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Orly Vardeny et al. JCHF 2016;4:152-158 Crude and Propensity-Adjusted Hazard Ratio for All-Cause Death, Cardiovascular Death or Heart Failure Hospitalization (Primary Endpoint), All-Cause Hospitalization, and Cardiopulmonary/Influenza-Related Hospitalization or Death Influenza vaccination was associated with a lower risk for all-cause death. In crude, but not propensity adjusted models, influenza vaccination was associated with a higher risk for hospitalizations. Orly Vardeny et al. JCHF 2016;4:152-158 2016 American College of Cardiology Foundation